Clinical Trial Update: Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating R3R01 in patients with Alport syndrome and focal segmental glomerulosclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alport Syndrome
• Focal Segmental Glomerulosclerosis

Drugs mentioned

• R3R01

Snippet

Sponsor: River 3 Renal Corp. | Conditions: Alport Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 | Status: COMPLETED